Trial Management Group
MAP.3 October Newsletter
|The October edition of the MAP.3 newsletter is now available ... http://www.ctg.queensu.ca/trials/breast/map3/map3.html. Please note that you will be asked for your userid and password.
MAP.3 or "ExCEL" is a phase III breast cancer prevention clinical trial. It is an important international clinical trial designed to determine whether a special type of medication can prevent breast cancer in healthy postmenopausal women who are at an increased risk for developing breast cancer.
Objectives of the study are to:
1. Determine if exemestane reduces the incidence of invasive breast cancer compared with placebo.
2. Determine if exemestane reduces the incidence of invasive and non-invasive (DCIS) breast cancer compared with placebo.
3. Compare the incidence of all clinical fractures.
4. Determine whether there are differences between exemestane and placebo with respect to the incidence of clinically relevant cardiac events.
5. Assess the impact, in comparison to placebo, of exemestane on menopausal symptoms and quality of life.
6. Determine whether there are significant differences in adverse events among the treatment arms.
7. Assess Quality of Life.
The ExCel research study is coordinated by the Canadian Cancer Trials Group in cooperation with Pfizer Inc., well women and cancer centers in Canada, the United States, Spain and France.
If you have questions or would like more information about the MAP.3 study, please contact Andrea Hiltz, Study Coordinator at firstname.lastname@example.org or 613-533-6430.